(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Yasser Abu Shabab's killing raises questions about Israel's militia strategy in Gaza- 'Seditious behavior': Trump accuses Democrats who made video reminding the military not to follow illegal orders of a crime — but is it?
- 6 Monetary Arranging Administrations for Your Necessities
- Study shows no clear link between low-fat dairy and dementia risk
- Avoid Large Crowds In Bali & Swim At This Peaceful Waterfall With A Gorgeous, Natural Pool
- Vote in favor of the bloom plan that adds a bit of excellence to your life!
- The most effective method to Shield Your Gold Ventures: Procedures and Precautionary measures
- High Court freezes government move to shutter Army Radio pending ruling
- IDF: Staying in West Bank refugee camps will quell lone-wolf terror
